Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.